Table 2 Patient characteristics
Had Mutation Test? | |||
|---|---|---|---|
Yes | No | P valuea | |
All Patients | 237 (80.3%) | 58 (19.7%) | |
Gender | |||
Female | 143 (79.9%) | 36 (20.1%) | 0.81 |
Male | 94 (81.0%) | 22 (19.0%) | |
Age distribution | |||
< 18 | 2 (100%) | 0 | 0.74 |
19 to 30 | 4 (66.7%) | 2 (33.3%) | |
31 to 45 | 34 (87.2%) | 5 (12.8%) | |
46–59 | 66 (79.5%) | 17 (20.5%) | |
60 to 74 | 103 (78.6%) | 28 (21.4%) | |
75+ | 28 (82.4%) | 6 (17.6%) | |
Unknown | |||
Country of Residence | |||
North America | 183 (78.9%) | 49 (21.1%) | 0.14 |
Europe | 25 (96.2%) | 1 (3.8%) | |
South America | 14 (77.8%) | 4 (22.2%) | |
Asia | 10 (90.9%) | 1 (9.1%) | |
Australia/New Zealand | 5 (62.5%) | 3 (37.5%) | |
Year of Diagnosis | |||
< 2000 | 2 (100%) | 0 | 0.35 |
2000–2004 | 26 (81.2%) | 6 (18.8%) | |
2005–2009 | 26 (68.4%) | 12 (31.6%) | |
2010–2014 | 68 (81.0%) | 16 (19%) | |
2015–2020 | 115 (80.3%) | 24 (17.3%) | |
Stage at Diagnosis | |||
Single tumor | 160 (80.4%) | 39 (19.6%) | 0.10 |
Multifocal tumor | 20 (87.0%) | 3 (13.0%) | |
Metastatic | 57 (78.1%) | 16 (21.9%) | |